Yasuaki Shida Selected Research

Factor VIIIa

3/2021	Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition.
1/2021	Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yasuaki Shida Research Topics

Disease

11	Thrombosis (Thrombus) 09/2022 - 01/2008
6	Hemophilia A (Haemophilia) 09/2022 - 01/2008
6	Hemorrhage 09/2022 - 09/2014
2	Type 2 von Willebrand Disease 03/2021 - 01/2021
1	Type 3 von Willebrand Disease 09/2022
1	Thrombotic Microangiopathies 03/2021
1	Thrombotic Thrombocytopenic Purpura 11/2017

Drug/Important Bio-Agent (IBA)

5	emicizumabIBA 09/2022 - 10/2019
5	von Willebrand FactorIBA 09/2022 - 09/2014
4	FibrinIBA 03/2021 - 01/2008
3	CollagenIBA 09/2014 - 02/2008
2	Factor VIIIaIBA 03/2021 - 01/2021
2	Hemostatics (Antihemorrhagics)IBA 03/2021 - 09/2014
2	Monoclonal AntibodiesIBA 11/2017 - 02/2008
1	recombinant FVIIa (rFVIIa)FDA Link 03/2021
1	prothrombin complex concentrates (PPSB)IBA 03/2021
1	ADAMTS13 ProteinIBA 04/2019
1	Therapeutic UsesIBA 01/2018
1	antineoplaston A10 (A 10)IBA 11/2017
1	thiamine triphosphorate (TTP)IBA 11/2017
1	platelet membrane glycoprotein VIIBA 09/2014
1	Glycoproteins (Glycoprotein)IBA 09/2014
1	ferric chlorideIBA 09/2014
1	IntegrinsIBA 09/2014
1	Cilostazol (Pletal)FDA LinkGeneric 09/2012
1	Fluorescent Dyes (Fluorescent Probes)IBA 09/2012
1	Tirofiban (Aggrastat)FDA Link 09/2012
1	Pravastatin (Pravachol)FDA LinkGeneric 02/2011
1	Factor VIIa (Activated Factor VII)IBA 01/2008

Therapy/Procedure

4	Therapeutics 03/2021 - 01/2008
1	Lasers (Laser) 01/2008